Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Neuro-Hitech, Inc.
(OP:
NHPI
)
0.0080
USD
-0.0015 (-15.79%)
Official Closing Price
/ Updated:
8:10 PM EDT, May 22, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
10,400
Open
0.0050
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0095
Today's Range
0.0050 - 0.0080
52wk Range
0.0003 - 0.0400
Shares Outstanding
31,520,186
Dividend Yield
N/A
Top News
More News
Neuro-Hitech, Inc. Announces Modification of Terms of Acquisition of MCR American Pharmaceuticals and AMBI Pharmaceuticals
November 19, 2008
from
Business Wire News Releases
Neuro-Hitech, Inc. Announces Acquisition of MCR American Pharmaceuticals
June 11, 2008
Closes on Equity Raise
Read More
from
Business Wire News Releases
More News
Read More
Neuro-Hitech Receives Notice of Delisting from NASDAQ
March 28, 2008
from
Business Wire News Releases
Neuro-Hitech Receives Delisting Warning Letter from NASDAQ
March 20, 2008
from
Business Wire News Releases
Neuro-Hitech, Inc. Announces Agreement with Numoda Corporation to Progress Development of Huperzine A in Alzheimer's Disease
March 07, 2008
from
Business Wire News Releases
Neuro-Hitech Receives Delisting Warning Letter from NASDAQ
February 22, 2008
from
Business Wire News Releases
Neuro-Hitech (NHPI) Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
February 01, 2008
from
StreetInsider.com News Articles
Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
February 01, 2008
from
Business Wire News Releases
Neuro-Hitech Announces Completion of Double-Blind Part of Phase Two Clinical Trial of Huperzine A in Alzheimer's Disease
December 14, 2007
from
Business Wire News Releases
Neuro-Hitech Announces Private Offering of $5.0 Million
November 29, 2007
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here